



ERIC HOLCOMB, GOVERNOR  
STATE OF INDIANA

***Office of Medicaid Policy and Planning***  
MS 07, 402 W. WASHINGTON STREET, ROOM W382  
INDIANAPOLIS, IN 46204-2739

## **MEETING AGENDA AND PUBLIC NOTIFICATION**

Therapeutics Committee

August 2, 2024

9:00 A.M. EDT

### **Hybrid Meeting**

Indiana State Government Center South

Conference Center Room C

Virtual Meeting Information Below

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of May 3, 2024
4. Preferred Drug List: Therapeutic Class Re-Review
  - a) Respiratory
    - i. Antihistamine-Decongestant Combinations/2<sup>nd</sup> Generation Antihistamines
    - ii. Antiviral Monoclonal Antibody
    - iii. Beta Adrenergics and Corticosteroids
    - iv. Beta Agonists
    - v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
    - vi. Leukotriene Receptor Antagonists
    - vii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
    - viii. Oral Inhaled Glucocorticoids



- ix. Pulmonary Antihypertensives
- x. Respiratory and Allergy Biologics
- b) Anti-Infectives
  - i. Antivirals - Anti-Herpetic Agents
  - ii. Antivirals - Influenza Agents
  - iii. Cephalosporins - 3<sup>rd</sup> Generation
  - iv. Fluoroquinolones
  - v. Hepatitis C Agents
  - vi. Macrolides
  - vii. Ophthalmic Antibiotics
  - viii. Ophthalmic Antibiotics/Corticosteroid Combinations
  - ix. Otic Antibiotics
  - x. Systemic Antifungals
  - xi. Topical Antifungals
  - xii. Topical Antivirals
  - xiii. Topical Antivirals and Anti-Inflammatory Steroid Combinations
  - xiv. Vaginal Antimicrobials
- c) Cardiovascular
  - i. Angiotensin-Converting Enzyme (ACE) Inhibitors
  - ii. ACE Inhibitor Combinations
  - iii. Angiotensin II Receptor Antagonists (ARBs)
  - iv. ARB Combinations
  - v. Beta Adrenergic Blockers
  - vi. Beta Adrenergic Blockers with Diuretics
  - vii. Calcium Channel Blockers (CCBs)
  - viii. Miscellaneous Cardiac Agents
- d) Lipotropics
  - i. Bile Acid Sequestrants
  - ii. Fibric Acid Derivatives
  - iii. HMG-CoA Reductase Inhibitors
  - iv. Lipotropics

- e) Antimigraine Agents
  - f) Electrolyte Depleters
  - g) Multiple Sclerosis Agents
  - h) Targeted Immunomodulators
  - i) Insulins (Off-Cycle Review)
- 5. New Business
  - 6. Public Comment
  - 7. Other Business
  - 8. Adjourn

---

## Microsoft Teams meeting

### **Join on your computer, mobile app or room device**

[Click here to join the meeting](#)

Meeting ID: 243 168 020 82

Passcode: kLmDSk

[Download Teams](#) | [Join on the web](#)

### **Join with a video conferencing device**

425899727@t.plcm.vc

Video Conference ID: 112 429 890 31

[Alternate VTC instructions](#)

### **Or call in (audio only)**

[+1 952-222-7450,,156327959#](#) United States, Bloomington

Phone Conference ID: 156 327 959#

[Find a local number](#) | [Reset PIN](#)

[Learn More](#) | [Help](#) | [Meeting options](#)